Corticorelin ovine triflutate
As of the edition of 20 October 2026, Corticorelin ovine triflutate is a protein: marketed, first approved in 1996 (US); US protection ended in 2008.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Protein
- Brand name
- Acthrel
- First approved
- 23 May 1996 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Ferring Pharmaceuticals
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Chemically induced; Hormones; Mental health; Nervous system
US protection
US protection ended in 2008.
US protection ended in 2008, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Ferring Pharmaceuticals. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ferring Pharmaceuticals | Applicant | 1996 to now |